LIVE
BEAM
Beam Therapeutics Inc. · Healthcare
$31.23
+7.58% this month
VERSUS
⟷
COMPARE
CRSP
CRISPR Therapeutics AG · Healthcare
$50.81
+2.03% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
BEAM
2
CRSP
2
Comparison scoreboard
MIXED SETUPAI Score
BEAM 33.2
CRSP ✓38.3
1Y Return
BEAM ✓+47.52%
CRSP -9.94%
Fwd P/E
BEAM ✓-6.60
CRSP -13.13
Target Up.
BEAM +64.45%
CRSP ✓+66.70%
Op. Margin
BEAM N/A
CRSP N/A
Metrics last refreshed: 7/14/2026
Quick take
BEAM vs CRSP: Beam Therapeutics vs CRISPR Therapeutics Stock Comparison: AI Score, Valuation, Performance and Upside
Beam Therapeutics is developing base editing technology as a potentially safer next-generation approach to gene correction, while CRISPR Therapeutics has already achieved the historic milestone of the world's first approved CRISPR therapy (Casgevy) with Vertex. CRSP has first-mover approval advantage; BEAM has a potentially safer technology platform that is still earlier-stage.
BEAM vs CRSP is next-generation base editing technology versus proven CRISPR therapy approval — CRISPR Therapeutics has validated the gene editing platform with Casgevy; Beam bets that base editing's precision will win in larger patient populations once clinical proof of concept is established.
Live analysis · updated 7/14/2026
BEAM and CRSP are closely matched — they split the tracked metrics evenly. BEAM leads on both 1-year return (+47.52%) and forward P/E quality (-6.60x vs -13.13x for CRSP), a relatively favorable combination of momentum and valuation. Analyst consensus implies similar upside for both: +64.45% for BEAM and +66.70% for CRSP.
Normalized 1Y performance
BEAM
CRSP
Recent returns
BEAM
CRSP
Analyst price targets & sentiment
BEAM · 14 analysts
STRONG BUYHOLDSTRONG SELL
Strong Buy (1.3/5.0)
Price target range
analyst low$26.00
analyst high$80.00
analyst mean$51.36
current price$31.23
+64.4% upside to analyst mean
CRSP · 20 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$44.00
analyst high$291.00
analyst mean$84.70
current price$50.81
+66.7% upside to analyst mean
Who should consider this stock?
BEAM may suit investors who:
- →believe base editing's precision and safety profile will surpass traditional CRISPR for broader patient populations
- →want earlier-stage genetic medicine exposure with higher risk and potential return
- →value Broad Institute licensing and David Liu's foundational base editing science
- →are comfortable with pre-approval clinical risk across multiple editing programs
CRSP may suit investors who:
- →prefer an approved CRISPR therapy with Casgevy generating commercial milestone and royalty revenue
- →value Vertex's commercial partnership for Casgevy as a risk-reducing structure
- →want gene editing exposure with at least one approved therapy de-risking the platform
- →are comfortable with hemoglobinopathy market limitations and CRSP's pipeline diversification risk
Performance & AI score
| Metric | BEAM | CRSP |
|---|---|---|
| AI score | 33.2 | 38.3 |
| AI rank | #2014 | #1357 |
| Latest close | $31.23 | $50.81 |
| 1M return | +7.58% | +2.03% |
| 6M return | -7.30% | -8.12% |
| 1Y return | +47.52% | -9.94% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BEAM | CRSP |
|---|---|---|
| 1Y ago | $14.75K (+47.5%) started 2025-07-14 | $9.01K (-9.9%) started 2025-07-14 |
| 5Y ago | $3.64K (-63.6%) started 2021-07-14 | $3.9K (-61.0%) started 2021-07-14 |
| 10Y ago | $16.66K (+66.6%) started 2020-02-06 | $36.06K (+260.6%) started 2016-10-19 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | BEAM | CRSP |
|---|---|---|
| Market cap | $3.21B | $5B |
| Trailing P/E | N/A | N/A |
| Forward P/E | -6.60 | -13.13 |
| Price/Sales | 19.59 | 1219.59 |
| EV/Revenue | 12.96 | 787.00 |
| Analyst target | $51.36 | $84.70 |
| Target upside | +64.45% | +66.70% |
Growth, profitability & risk
| Metric | BEAM | CRSP |
|---|---|---|
| Revenue growth | 324.90% | 68.60% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | -142.40% | -6358.66% |
| Operating margin | N/A | N/A |
| Profit margin | -40.23% | 0.00% |
| ROIC proxy | -5.77% | -31.21% |
| Return on equity | -5.77% | -31.21% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 2.18 | 1.70 |
| Debt/equity | 21.54 | 43.41 |
| Current ratio | 16.99 | 17.96 |
| Quick ratio | 16.25 | 17.92 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
BEAM max drawdown38.15%
CRSP max drawdown42.25%
BEAM max wkly drop17.64%
CRSP max wkly drop18.19%
5Y risk snapshot
BEAM max drawdown87.25%
CRSP max drawdown77.31%
BEAM max wkly drop31.25%
CRSP max wkly drop21.49%
10Y risk snapshot
BEAM max drawdown89.12%
CRSP max drawdown85.11%
BEAM max wkly drop41.11%
CRSP max wkly drop30.47%
Performance metrics by period
| Period | Metric | BEAM | CRSP |
|---|---|---|---|
| 1Y | Growth | +47.52% | -9.94% |
| CAGR | +47.56% | -9.95% | |
| Sharpe ratio | 0.83 | 0.07 | |
| Max drawdown | 38.15% | 42.25% | |
| Max daily drop | 10.48% | 11.59% | |
| Max wkly drop | 17.64% | 18.19% | |
| 5Y | Growth | -63.57% | -61.01% |
| CAGR | -18.29% | -17.17% | |
| Sharpe ratio | 0.04 | -0.09 | |
| Max drawdown | 87.25% | 77.31% | |
| Max daily drop | 19.32% | 13.32% | |
| Max wkly drop | 31.25% | 21.49% | |
| 10Y | Growth | +66.56% | +260.61% |
| CAGR | +8.25% | +14.09% | |
| Sharpe ratio | 0.44 | 0.45 | |
| Max drawdown | 89.12% | 85.11% | |
| Max daily drop | 23.42% | 17.10% | |
| Max wkly drop | 41.11% | 30.47% |
Business comparison
| Category | BEAM | CRSP |
|---|---|---|
| Company | Beam Therapeutics Inc. | CRISPR Therapeutics AG |
| Sector | Healthcare | Healthcare |
| Industry | N/A | N/A |
| Core business | Biotechnology company developing base editing medicines that correct disease-causing mutations without making double-strand DNA breaks. Beam's technology is derived from the work of David Liu at the Broad Institute and is viewed as a potentially safer approach than traditional CRISPR. | Gene editing company that co-developed Casgevy (exa-cel), the first approved CRISPR-based therapy for sickle cell disease and beta-thalassemia, with Vertex Pharmaceuticals. CRISPR Therapeutics also has a pipeline in diabetes (CTX112) and oncology. |
| Investor focus | Base editing IND filings and clinical trial advancement, hematology programs (sickle cell, beta-thalassemia), in vivo base editing development, and cash runway. | Casgevy commercial ramp and revenue sharing with Vertex, CTX112 diabetes clinical progress, CAR-T oncology pipeline advancement, and in vivo gene editing development. |
BEAM strengths
- →Base editing technology may offer a safer, more precise approach to gene correction than traditional CRISPR-Cas9 double-strand breaks
- →Broad Institute licensing provides access to a world-class genomics IP portfolio
- →Strong founding science from David Liu's Harvard lab provides credibility and depth of foundational technology
CRSP strengths
- →Casgevy is the world's first approved CRISPR therapy — a historic milestone that validates the platform and generates commercial revenue
- →Vertex partnership provides commercial infrastructure and expertise for Casgevy launch without CRSP incurring full commercial buildout costs
- →Strong cash position from Vertex milestone payments provides multi-year runway
Risks to watch — BEAM
- →Base editing is earlier-stage than CRISPR's approved therapies — clinical proof of concept is not yet established
- →Cash burn in discovery-stage biotech is high relative to current revenue
- →CRISPR Therapeutics has an approved therapy (Casgevy) — Beam must demonstrate it can close this competitive gap
Risks to watch — CRSP
- →Casgevy's one-time high cost ($2M+) and complex treatment process limit the addressable patient population
- →In vivo CRISPR delivery remains challenging — most approved applications require ex vivo cell editing
- →Pipeline diversification from hemoglobinopathies into diabetes and oncology requires clinical execution
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →